1) is a m-opioid receptor (MOR) agonist and it does not easily pass through the blood-brain barrier (BBB). Therefore, it is now mainly used as an antidiarrheal. But recently, it has been reported that when loperamide was administered to a burn on a rat as a peripheal percutaneous cream, it was effective and could not easily pass through the BBB so the manifestion of tolerance did not occur.
New m m-Opioid Receptor Agonists with Phenoxyacetic Acid Moiety
shown in Charts 2 and 3. The 1-benzyl-4-hydroxy-4-(benzyloxyphenyl)piperidine derivatives (3a-c) were synthesized from 1-benzyl-4-piperidinone (1) and benzyloxyphenylmagnesium bromide (2) according to the scheme shown in Chart 2. The 4-hydroxy-4-(hydroxyphenyl)piperidine derivatives (4a-c) were prepared according to the procedure described in our another previous paper. 4) The N-substituted derivatives (6a-c) were obtained by the reaction of 4a-c with dimethyl(tetrahydro-3,3-diphenyl-2,2-furylidene) ammonium bromide (5) , which was prepared according to the procedure of Stokbroekx et al. 1) The phenoxyalkylalcohol derivatives [7a(I)-7c(I), 7a(II)-7a(IV)] were obtained from the reaction of 6 with w-bromoalkyl acetate followed by alkaline hydrolysis at room temperature as shown in Chart 2.
The O-acetic acid (8), the O-methoxylethyl (9) and the Oacetamide (10) derivatives were synthesized as shown in Chart 3. The O-acetic acid derivative (8) was synthesized by the reaction of 6a with ethyl bromoacetate followed by alkaline hydrolysis. Compounds 9 and 10 were prepared by the reaction of 6a with 2-methoxyethyl bromide and 2-bromoacetamide, respectively.
The piperidine derivatives (14y, 15y) were synthesized from 4-(2-hydroxyphenyl)piperidine (12y), which was prepared according to the procedure described in the previous paper, 4) as shown in Chart 4. The reaction of 4-(2-hydroxyphenyl)piperidine (12y) with 5 gave the butanamide (13y), which was allowed to react with 2-bromoethyl acetate or ethyl bromoacetate followed by alkaline hydrolysis to give the 2-phenoxyethanol (14y) or the phenoxyacetic acid (15y), respectively.
The piperazine derivatives (14z, 15z), were synthesized from the commercially available 1-(2-methoxyphenyl)piperazine (11z) as shown in Chart 4. 1-(2-Methoxyphenyl)piperazine (11z) was demethylated with aqueous hydrobromic acid to 1-(2-hydroxyphenyl)piperazine (12z) followed by the same procedure as described for the synthesis of 14y or 15y to give the 2-phenoxyethanol (14z) or the 2-phenoxyacetic acid (15z).
Agonist Activities, Binding Assays and Analgesic Effects
Each sample was converted to the HCl salt to increase it's solubility in water for the assays mentioned below and then converted into an amorphous powder.
As the first screening, we examined the potencies of the samples relative to that of [D-Ala 2 , N-MePhe 4 , Gly 5 -ol]-enkephalin (DAMGO), which is highly selective MOR agonist in the guinea-pig ileum. Next, we checked the human MOR, DOR and KOR binding assays to confirm the selectivity of the chosen sample. Finally, we examined the peripheral analgesic effect of the sample using the Randal-Selitto method on rat as an in vivo test.
First, when the substitution position of the 2-hydroxyethoxy moiety on the phenyl group of 7a(I) was changed from ortho to meta or para, the meta-substituted compound 7b(I) showed an extremely lower MOR agonist potency than 7a(I) while para-substituted compound 7c(I) did not show any agonist activity (Table 4A) .
We then examined the length of the carbon chain between the phenoxy moiety and the terminal hydroxy group of 7a(I). The MOR agonist potencies of 7a(II), 7a(III) and 7a(IV) having the 2-hydroxyethoxy moiety of 7a(I) replaced with the 3-hydroxypropyloxy moiety, 4-hydroxybutyloxy moiety and 6-hydroxyhexyloxy moiety, respectively, were evaluated. Among them, 7a(II) and 7a(III) showed lower MOR agonist potencies than 7a(I), while 7a(IV) did not show any agonist activity (Table 4A) .
Therefore, considering the length of the carbon chain of 7a(I), the MOR agonist potencies of 8, 9 and 10 having the 2-hydroxyethoxy moiety of 7a(I) replaced with carboxymethoxy moiety, the 2-methoxyethoxy moiety and the carbamoylmethoxy moiety were evaluated. Among them, 8 showed a higher MOR agonist potency than 7a(I) and the potency of 8 was 47 times higher than that of DAMGO. Compounds 9 and 10 had lower MOR agonist potencies than 8 (Table 4A) .
Finally, we examined the activities of the piperidine derivatives and the piperazine derivatives of 7a(I) and 8. Namely, the MOR agonist potencies of 14y and 14z having the 4-hydroxypiperidine moiety of 7a(I) replaced with the piperidine moiety and piperazine moiety, respectively, were evaluated, and the above potencies of 15y and 15z having the 4-hydroxypiperidine moiety of 8 replaced with piperidine moiety and piperazine moiety respectively were evaluated. Similar to the results of 7a(I) and 8, the potency of the phenoxyacetic acid type, 15y or 15z, was higher than that of the 2-phenoxyethyl alcohol type, 14y or 14z (Table 4B) .
Here, we would like to review our piperazine derivatives. Compounds 14z and 15z have the methoxy moiety of our previous lead compound A replaced with the 2-hydroxyethoxy moiety and the carboxymethoxy moiety, respectively. Among them, 15z showed 4 times more potent MOR agonist activity but 15y showed almost the same MOR agonist potency compared to A. Then we could confirm that 15z has the highest MOR agonist potency among our piperazine derivatives.
As mentioned above, the phenoxyacetic acid derivatives showed higher MOR agonist potencies than the 2-phenoxyethyl alcohol derivatives, and for the phenoxyacetic acid derivatives, the 4-hydroxypiperidine derivative 8 had the 
The % inhibition of the stimulated muscle twitch produced by a compound was plotted against the log concentration (10 Ϫ5 -10 Ϫ11 M) of the compound to estimate the IC 50 (concentration of the compound to produce 50% inhibition of the twitch). The relative potencies of the test compounds were calculated by the following formula: relative potencyϭDAMGO's IC 50 /compound's IC 50 . The test compounds were confirmed to be an opioid agonist by antagonism of naloxone (sufficiently at 10 Ϫ8 M). Furthermore, the compounds showing over 4.0 in the value of relative potency were evaluated precisely (Table 4B ). highest potency (Table 4B) . Next, we examined the affinities to the human MOR, DOR and KOR to confirm the selectivity of the most potent MOR agonist, 8 (Table 5 ). We then confirmed that it had the selectivity to the MOR because it showed lower affinities to the DOR and KOR than to the MOR.
Lastly, we examined the peripheral analgesic activity of compound 8 in the Randal-Selitto method on rat as an in vivo test. As shown in Fig. 2 , compound 8 had peripheral analgesic activity because the effect was inhibited by naloxone methiodide of the peripheral opioid receptor antagonist.
Conclusion
As mentioned above, we found compound 8 (SS620) having a 10 times more potent MOR agonist activity than loperamide and a potent peripheral analgesic activity in vivo. Therefore, we selected compound 8 as one of the promising candidates for a peripheral analgesic of the MOR agonist and are now running various pharmacological tests to confirm its profile. Also, we are continuing to examine the precise structure-activity relationship, and some derivatives of compound 8 are now being synthesized and evaluated.
Experimental
Melting points were determined on a Yanaco micro melting point apparatus without correction. IR spectra were measured with a Perkin-Elmer 1600 FT-IR spectrometer.
1 H-NMR spectra were recorded on a JEOL JNM-EX400 FT-NMR spectrometer in CDCl 3 or dimethyl sulfoxide (DMSO)-d 6 using tetramethylsilane as the internal reference. The following abbreviations were used: sϭsinglet, dϭdoublet, ddϭdouble doublet, dtϭdouble triplet, tϭtriplet, qϭquartet, mϭmultiplet and brϭbroad. FAB-MS, electron ionization mass spectrometry (EI-MS) or high-resolution mass spectra (HR-MS) were obtained using JEOL JMS-DX303 or JEOL JMS-AX500 mass spectrometer. TLC was performed by using Silica gel 60F 254 (Merck). Column chromatography was performed with Silica gel 60 (70-230 mesh) (Merck). Sodium sulfate was employed as the drying agent. Palladium hydroxide [20 wt%, Pd (dry basis) on carbon, wet] and hydrogen chloride, 1.0 M solution in diethyl ether were obtained from Aldrich Chemical Company, Inc. The yields, physical and spectral data for 7a (I)-7a(IV), 7b(I),  7c(I), 8-10, 14y, 14z, 15y and 15z are shown in Tables 1 and 2 . The analytical data for the solid compounds among the above compounds, 7a(I),  7a(II), 7a(III), 8, 10, 15y and 15z , are shown in Table 3 .
4-Hydroxy-4-(3-hydroxyphenyl)piperidine (4b) 4) Typical Procedure: A solution of 1-benzyl-4-[3-(benzyloxy)phenyl]-4-hydroxypiperidine (3b) (10.0 g, 26.8 mmol) in MeOH (100 ml) was hydrogenated in the presence of Pd(OH) 2 (3.0 g) under H 2 atmosphere (4 atm) at room temperature for 6 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to give 4b (4.00 g, 77%) as a colorless solid. mp 188-189°C. 1-(2-Hydroxyphenyl)piperazine (12z) A mixture of 1-(2-methoxyphenyl)piperazine (11z) (1.00 g, 5.20 mmol) and 48% hydrobromic acid (15.0 ml, 278 mmol) was stirred at 140°C for 6 h. After cooling, the mixture was made alkaline with 3 N NaOH to pH 9. The resulting precipitate was collected by filtration, washed with water, air-dried at room temperature to give 12z (500 mg, 54%) as an yellowish solid. mp 118-120°C. 2 mmol) , potassium carbonate 300 mg (2.2 mmol) and N,N-dimethylformamide (DMF) (15 ml) was stirred at 40°C for 4 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in a mixture of 1 N NaOH (10 ml), MeOH (10 ml) and 1,4-dioxane (10 ml), then stirred at room temperature for 1 h. The mixture was neutralized with dil. HCl to pH 7 at 0°C. The mixture was extracted with CHCl 3 , washed with H 2 O, dried, and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with 5% MeOH in CHCl 3 to give 7 or 8 as a colorless solid or yellowish viscous liquid.
Compounds 7a(I)-7a(IV), 7b(I), 7c(I) and 8 were synthesized from 6 according to the general procedure C. N,N-Dimethyl-2,2-diphenyl-4-[4-[2-(2-hydroxyethoxy) 3 H]DPN The assays mentioned above were performed according to the procedures described in our previous paper.
N,N-Dimethyl-2,2-diphenyl-4-[4-[2-(2-hydroxyethoxy)phenyl]piperidin-

3)
Animals The experiment was performed on male Sprague-Dawley rats weighing 110-150 g (Charles River, Japan). The animals were housed under 12-h light-dark cycle (lights on 7 : 00 a.m.), with room temperature maintained 23Ϯ3°C, and humidity at 50Ϯ20%. Food and water were freely available.
Materials Naloxone methiodide and Freund's complete adjuvant (FCA) were obtained from Sigma. Naloxone methiodide was diluted in saline and injected (10 mg/kg) by subcutaneous route in a volume of 2 ml/kg body weight 15 min before compound treatment. Compound was diluted in 5% dimethylsulfoxide-0.5% carboxymethylcellulose sodium-saline and injected by intraplantar route in a volume of 50 ml/site.
Analgesic Assay A modification of the methods of Dehaven-Hudkins et al. 5) was used, where hyperalgesia in response to inflammation was measured by determining the paw pressure threshold of inflamed paw using a pressure analgesia apparatus (Ugo Basile, Italy). Hyperalgesia was induced by subcutaneously injection of 150 ml of FCA into the right hind paw of rats. Compound was subcutaneously injected into the inflamed paw approximately 24 h after FCA injection. The experimenter was unaware of the compound used.
